...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: A trial on pigs
【24h】

Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: A trial on pigs

机译:电子控制的口内装置经颊腔给药后纳曲酮的体内生物利用度:在猪上的试验

获取原文
获取原文并翻译 | 示例
           

摘要

Naltrexone (NLX), an opioid antagonist, is widely used in the treatment of opiate addiction, alcoholism and smoking cessation. Its current peroral administration induces various adverse side effects and has limited efficacy since bioavailability and patient compliance are poor. The development of a long-acting drug delivery system of NLX may overcome the current drawbacks and help in the improvement of treatment of addiction. The primary endpoints of this study were: a) to compare the NLX bioavailability and pharmacokinetics after delivering a single transbuccal dose, released by a prototype of intraoral device, . versus an intravenous (I.V.) bolus of the same drug dose; b) to verify the functioning of a prototype of a new intraoral device . in vivo; c) to evaluate the permeation enhancement effect of iontophoresis; d) to assess any histomorphological changes in the buccal mucosa after transbuccal delivery. The system was tested on 6 pigs in a cross-over trial. Venous blood samples were drawn at a fixed timetable from the beginning of drug administration and analyzed for the presence of NLX, using an LC/MS/MS method. A punch biopsy was performed for histological analysis after the final experiment. The administration of I.V. NLX induced a sharp increase in blood levels after 5. min and then a steep decrease. In contrast, transmucosal delivery resulted in a gradual increase in blood NLX levels, reaching its peak after 90. min, followed by a slow decrease. After 6. h the blood levels of NLX delivered through the buccal mucosa were higher as compared to I.V. administration. No signs of flogosis or tissue damage were histologically highlighted. These results suggest that buccal delivery by an intraoral electronic device could potentially induce long-lasting, continuous and controlled blood levels of NLX, avoiding at the same time spikes of drug plasma levels typical of the I.V. administration route.
机译:阿片拮抗剂纳曲酮(NLX)被广泛用于治疗阿片成瘾,酗酒和戒烟。由于生物利用度和患者依从性差,其目前的经口给药引起各种不良副作用并且疗效有限。 NLX长效药物递送系统的开发可以克服当前的弊端,并有助于改善成瘾的治疗。这项研究的主要终点是:a)比较经口腔内器械原型释放的单次经颊剂量后NLX的生物利用度和药代动力学。与相同药物剂量的静脉推注相比b)验证新的口内装置原型的功能。体内; c)评价离子电渗疗法的渗透增强作用; d)评估经颊输送后颊粘膜的任何组织形态学变化。该系统在交叉试验中对6头猪进行了测试。从给药开始就在固定的时间表上抽取静脉血样品,并使用LC / MS / MS方法分析NLX的存在。最终实验后进行穿孔活检以进行组织学分析。 I.V.的管理NLX在5分钟后诱导血液水平急剧上升,然后急剧下降。相反,透粘膜递送导致血液中NLX水平逐渐升高,在90分钟后达到峰值,然后缓慢降低。在6小时后,通过颊粘膜递送的NLX的血液水平高于IV。行政。在组织学上没有突出突出或组织损伤的迹象。这些结果表明,通过口内电子设备进行颊部递送可能潜在地引起NLX的长期,连续和受控血药水平,同时避免了典型的I.V.血浆药物浓度峰值。管理途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号